These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice. Nonogaki K, Nozue K, Oka Y. Endocrinology; 2006 Dec; 147(12):5893-900. PubMed ID: 16973729 [Abstract] [Full Text] [Related]
4. Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Mongeau R, Weiss M, de Montigny C, Blier P. Neuropharmacology; 1998 Jul; 37(7):905-18. PubMed ID: 9776386 [Abstract] [Full Text] [Related]
6. Acute effect of milnacipran on the relationship between the locus coeruleus noradrenergic and dorsal raphe serotonergic neuronal transmitters. Bandoh T, Hayashi M, Ino K, Takada S, Ushizawa D, Hoshi K. Eur Neuropsychopharmacol; 2004 Dec; 14(6):471-8. PubMed ID: 15589386 [Abstract] [Full Text] [Related]
10. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Leo RJ, Brooks VL. Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117 [Abstract] [Full Text] [Related]
11. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. Rénéric JP, Bouvard M, Stinus L. Neuropsychopharmacology; 2001 Apr; 24(4):379-90. PubMed ID: 11182533 [Abstract] [Full Text] [Related]
12. Milnacipran, a serotonin and noradrenaline reuptake inhibitor, suppresses long-term potentiation in the rat hippocampal CA1 field via 5-HT1A receptors and alpha 1-adrenoceptors. Tachibana K, Matsumoto M, Togashi H, Kojima T, Morimoto Y, Kemmotsu O, Yoshioka M. Neurosci Lett; 2004 Mar 04; 357(2):91-4. PubMed ID: 15036582 [Abstract] [Full Text] [Related]
13. Orexigenic effects of endomorphin-2 (EM-2) related to decreased CRH gene expression and increased dopamine and norepinephrine activity in the hypothalamus. Brunetti L, Ferrante C, Orlando G, Recinella L, Leone S, Chiavaroli A, Di Nisio C, Shohreh R, Manippa F, Ricciuti A, Mollica A, Vacca M. Peptides; 2013 Oct 04; 48():83-8. PubMed ID: 23916912 [Abstract] [Full Text] [Related]
16. Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action. Bourin M, Masse F, Dailly E, Hascoët M. Pharmacol Biochem Behav; 2005 Jul 04; 81(3):645-56. PubMed ID: 15961146 [Abstract] [Full Text] [Related]
17. Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice. Sugimoto Y, Tagawa N, Kobayashi Y, Hotta Y, Yamada J. Biol Pharm Bull; 2007 Dec 04; 30(12):2399-401. PubMed ID: 18057733 [Abstract] [Full Text] [Related]
18. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP. Neuropharmacology; 2003 Dec 04; 45(7):935-44. PubMed ID: 14573386 [Abstract] [Full Text] [Related]
19. Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice. Nonogaki K, Nozue K, Oka Y. Biochem Biophys Res Commun; 2006 Dec 29; 351(4):1078-82. PubMed ID: 17097612 [Abstract] [Full Text] [Related]
20. Opposite effects of milnacipran, a serotonin norepinephrine reuptake inhibitor, on the levels of nitric oxide and brain-derived neurotrophic factor in mouse brain cortex. Ikenouchi-Sugita A, Toyohira Y, Yoshimura R, Ueno S, Tsutsui M, Nakamura J, Yanagihara N. Naunyn Schmiedebergs Arch Pharmacol; 2009 Dec 29; 380(6):479-86. PubMed ID: 19894036 [Abstract] [Full Text] [Related] Page: [Next] [New Search]